Premium
Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease
Author(s) -
Shanker Vicki,
Groves Mark,
Heiman Gary,
Palmese Christina,
SaundersPullman Rachel,
Ozelius Laurie,
Raymond Deborah,
Bressman Susan
Publication year - 2011
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.23746
Subject(s) - mood , leucine rich repeat , cognition , parkinson's disease , psychology , disease , lrrk2 , neuroscience , medicine , kinase , psychiatry , genetics , biology
The behavioral and cognitive features of the leucine‐rich repeat kinase G2019S mutation in Parkinson's disease in the Ashkenazi Jewish population are not well described; therefore, we sought to more systematically characterize these features using a semistructured psychiatric interview and neuropsychological testing. Twenty‐one Ashkenazi Jewish patients having the leucine‐rich repeat kinase G2019S mutation were compared with age‐ and sex‐matched Ashkenazi Jewish patients with Parkinson's disease without mutations. Although overall rates of affective disorders were not greater in mutation carriers, the carriers exhibited a 6‐fold increased risk of premorbid affective disorders (odds ratio, 6.0; P = .10), as determined by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders–IV. Of interest, we identified 2 leucine‐rich repeat kinase carriers with bipolar disorder; no mutation‐negative subjects had this diagnosis. Performance on the Hopkins Verbal Learning Test–Revised, Judgment of Line Orientation, and Frontal Assessment Battery was consistent with previous reports and did not differ between groups. Study findings suggest a possible association between premorbid mood disorders and leucine‐rich repeat kinase Parkinson's disease, warranting further evaluation. © 2011 Movement Disorder Society